POM-V Prescription Required

Equip EHV1,4 Suspension for Injection

Active ingredients: Equine herpesvirus 1, Equine herpesvirus 4

Form

Injection

Species

Horses

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5162

What it's used for

For active immunization of horses to reduce clinical signs and to reduce virus excretion during respiratory disease caused by equine herpesvirus type 1 (EH...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Equine herpesvirus 1 + Equin...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Equip EHV1,4 Suspension for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For active immunization of horses to reduce clinical signs and to reduce virus excretion
during respiratory disease caused by equine herpesvirus type 1 (EHV-1) infections.
Onset of immunity: 2 weeks after the second vaccine injection
Duration of immunity has only been demonstrated after the administration of three
vaccine injections (see section 4.9): 6 months after the 3rd vaccine injection.
For active immunisation of pregnant mares to reduce the occurence of abortions
caused by equine herpesvirus type 1 (EHV-1) infections.
Onset immunity: 3 weeks after the 3rd vaccine injection during gestation
Duration of immunity: until the end of pregnancy.

Revised: March 2025
AN: 03754/2024

Primary course: A single dose should be administered from 5 months of age followed by
a second injection after an interval of 4 to 6 weeks.
In the event of increased infection risk, for example when a foal had consumed insufficient
colostrum or there is a risk of early exposure to field infections with EHV-1 or EHV-4,
earlier vaccination may be given. In these circumstances, the foal should receive a single
dose from 3 months of age followed by the above mentioned full primary vaccination
course.
Booster: Following completion of the primary course, a single dose should be
administered every 6 months.
Use in pregnant mares: To reduce abortion due to EHV-1 infection, pregnant mares
should be vaccinated during the 5
th
, 7
th
, and 9
th
month of pregnancy with a single 1.5 ml
dose on each occasion.

None.

Horses:
Very common
(>1 animal / 10 animals treated):
Injection site swelling
Common
(1 to 10 animals / 100 animals treated):
Elevated temperature
Rare
(1 to 10 animals / 10,000 animals
treated):
Stiff gait
Anorexia, Lethargy
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Hypersensitivity reaction
1
Transient. Up to 5 cm in diameter, disappearing within a few to 6 days post vaccination.
Transient. Up to 2 days following dosing not exceeding 1.7°C.
Appropriate treatment is recommended / treat symptomatically.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

Vaccinate healthy animals only.

Special precautions for safe use in the target species:The vaccine may not be effective in
animals incubating the disease at the time of vaccination.
In the event of an allergic or anaphylactic reaction, immediate treatment should be given
with a soluble glucocorticoid intravenously (e.g. dexamethasone sodium phosphate),
adrenaline intramuscularly or antihistamine intramuscularly. Animals that have received
immunosuppressive drugs (e.g. glucocorticoids) should not be vaccinated until an interval
of at least 4 weeks has elapsed.
Syringes and needles should not have been sterilised chemically or be above ambient
temperature. Do not use chemicals to disinfect or sterilise the skin.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Not applicable.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be made on a case-by-case basis.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.
Store in the original package.
Protect from light.

Zero days.
4. IMMUNOLOGICAL INFORMATION
4.1 ATCvet code: QI05AA05
To stimulate active immunity against equine herpesvirus 1 and 4.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.